_thumb.png)
Research efforts and reports focused on event data have one overarching finding in common. Corporate events, especially revisions to previously scheduled events, can cause volatility. Understanding the types of events, event changes and other event-relate
Read More
Traders are gearing up for another earnings season. S&P 500 companies have handily beaten analyst expectations in each of the last four reporting periods, so expectations are likely growing loftier.
Read More
2020 was a year we will never forget for reasons beyond trading. The last 15 months might have marked a turning point in the healthcare sector specifically regarding the drug development and approval process. The FDA even said that 2020 was a strong year
Read More
The Q1 and Q2 2021 earnings seasons were perhaps the best in history relative to expectations. FactSet notes that for Q2, 86% of S&P 500 companies beat on the bottom line, and maybe more impressively, 76% of firms reported a positive revenue surprise.
Read More
PDUFA dates and content are essential for portfolio managers of healthcare stocks. A single positive or negative announcement from the US Food and Drug Administration (FDA) can send shares of a biotech firm soaring or turn a hot name quickly into a bear m
Read More
As inflation fears continue to ramp up and earnings season subsides, volatility has returned to global equity markets.
Read More
